Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (1668)	4/17/1999 4:02:00 PM
From: Mark Bartlett	Read Replies (1) \| Respond to of 14101

Bluejay, <<The data on Celebrex was far more extensive and convincing >> While their data may have been convincing enough to get approved faster, if one is to believe Rebecca's comments, it may not be much better in preventing some of the side-effects, than the old NSAIDS. From DMX site: The new COX-2 NSAID however, carries many of the same warnings of serious side effects as did the older NSAIDs. Just like the dozens of other NSAIDs on the market in the US (there are no COX-2 NSAIDs yet approved in Canada), the only approved COX-2 NSAID also carries warnings about the risk of gastrointestinal (GI) ulceration, bleeding and perforation as well as warnings about kidney (renal) injury. Indeed, serious, clinically significant upper GI bleeding has been observed in patients receiving this new COX-2 NSAID in both controlled and open-labelled trials, albeit infrequently. As with the older NSAIDs, the risk of GI bleeding increases where the patient is also being treated with oral corticosteroids or anticoagulants and either smokes or is older in age. Clinical trials with the new COX-2 NSAID have shown renal effects similar to those observed with older NSAIDs. As fluid retention and edema have been observed in some patients taking the new COX-2 NSAID, its use is recommended with caution in patients with fluid retention, hypertension or heart failure. Nor surprisingly, the incidence of adverse effects tended to be higher in elderly patients. **************** MB